Tirtha Chakraborty
Directeur Technique/Scientifique/R&D chez VOR BIOPHARMA INC.
Fortune : 304 696 $ au 30/04/2024
Postes actifs de Tirtha Chakraborty
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| VOR BIOPHARMA INC. | Directeur Technique/Scientifique/R&D | 01/11/2020 | - |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Consultant / Advisor | 24/07/2023 | - |
Historique de carrière de Tirtha Chakraborty
Anciens postes connus de Tirtha Chakraborty
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01/10/2018 | 01/10/2019 |
| CRISPR THERAPEUTICS AG | Directeur/Membre du Conseil | 01/01/2015 | 01/10/2018 |
| Corporate Officer/Principal | 01/01/2015 | 01/10/2018 |
Formation de Tirtha Chakraborty
| Tata Institute of Fundamental Research | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Suisse | 2 |
| Inde | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| VOR BIOPHARMA INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| Entreprise privées | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Bourse
- Insiders
- Tirtha Chakraborty
- Expérience
